The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 14, 2021

Filed:

Nov. 30, 2017
Applicant:

Glaxosmithkline Intellectual Property Development Limited, Middlesex, GB;

Inventors:

Olena I. Barbash, Collegeville, PA (US);

Andy Fedoriw, Collegeville, PA (US);

Sarah Gerhart, Collegeville, PA (US);

Ryan G. Kruger, Collegeville, PA (US);

Jenny Laraio, Collegeville, PA (US);

Helai Mohammad, Collegeville, PA (US);

Shane W. Obrien, Collegeville, PA (US);

Jacob Rubin, Collegeville, PA (US);

Niyant Shah, Collegeville, PA (US);

Ping Zhang, Collegeville, PA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/415 (2006.01); A61K 31/506 (2006.01); A61P 35/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/415 (2013.01); A61P 35/04 (2018.01);
Abstract

The present invention provides a combination of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The present invention also provides methods for treating cancer in a human in need thereof, the methods comprising administering to the human a combination of a Type I PRMT inhibitor and a Type II PRMT inhibitor, together with at least one of: a pharmaceutically acceptable carrier and a pharmaceutically acceptable diluent, thereby treating the cancer in the human. The present invention further provide a pharmaceutical composition comprising a therapeutically effective amount of a Type I PRMT inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a Type II PRMT inhibitor.


Find Patent Forward Citations

Loading…